Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.
The global anxiety disorders and depression treatment market, valued at approximately USD 11.2 billion in 2021, is on track ...
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. The FDA has greenlighted Novartis’ Kisqali, used in ...
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce ...
Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...
SEOUL/TOKYO, Sept 18 (Reuters) - North Korea fired multiple short-range ballistic missiles on Wednesday toward its east coast, South Korea and Japan said, days after Pyongyang unveiled a uranium ...
Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Washington and Seoul may strike a cost-sharing agreement for US forces based in South Korea before the end of the year — even though the current agreement does not expire until the end of ...
South Korea's military removed 1,300 cameras from its bases after discovering they were Chinese-made. The CCTV cameras were designed to be able to connect to a server in China, a Korean official said.
Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...